Emmaus Life SciencesEMMA -16.67% Current Ratio is 0.08 as of Mar. 2026, which is 73% below its 10-year median of 0.30. The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Emmaus Life Sciences ranks worse than 97.6% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Emmaus Life Sciences's current ratio for the quarter that ended in Mar. 2026 was 0.08.
Emmaus Life Sciences has a current ratio of 0.08. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Emmaus Life Sciences has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Emmaus Life Sciences's Current Ratio or its related term are showing as below:
EMMA'
s Current Ratio Range Over the Past 10 Years
Min: 0.07 Med: 0.3 Max: 3.69
Current: 0.08
During the past 13 years, Emmaus Life Sciences's highest Current Ratio was 3.69. The lowest was 0.07. And the median was 0.30.
EMMA's Current Ratio is ranked worse than 97.6% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs EMMA: 0.08
Emmaus Life Sciences (OTCPK:EMMA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Emmaus Life Sciences Current Ratio Related Terms
Emmaus Life Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs CERO, AGTX, WINT: Current Ratio Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Current Ratio of 0.08 as of Mar. 2026. This is 73% below median its historical median of 0.30. Over the past decade, Emmaus Life Sciences' Current Ratio has ranged from 0.07 to 3.69. According to the industry distribution chart, Emmaus Life Sciences ranks #1383 out of 1417 companies in the Biotechnology industry, placing it in the top 97.6%.
Is Emmaus Life Sciences' Current Ratio too high?
Emmaus Life Sciences' current Current Ratio of 0.08 is 73% below median its 10-year median of 0.30. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 3.69. The Biotechnology industry median Current Ratio is 3.89. Emmaus Life Sciences' value of 0.08 is 97.9% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #1383 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Current Ratio compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #1383 out of 1417 companies for Current Ratio. This places Emmaus Life Sciences in the lower half of its industry. The industry median Current Ratio is 3.89. Emmaus Life Sciences' value of 0.08 is 97.9% below this benchmark. Historically, Emmaus Life Sciences' own Current Ratio has ranged from 0.07 to 3.69 over the past decade. While the company's 10-year median is 0.30 vs. the industry median of 3.89, Emmaus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Current Ratio of 0.08 is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Current Ratio is 0.08, which is 73% below median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Current Ratio is 0.08, which is 73% below median its 10-year median of 0.30 and 97.9% below the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Current Ratio is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 